Therapeutic implications of the MDR-1 gene

Journal of Veterinary Pharmacology and Therapeutics

Volumn 27, Issue 5, 2004, Pages 257-264

  Mealey, Katrina L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CYCLOSPORIN; DACTINOMYCIN; DIGOXIN; DILTIAZEM; DOCETAXEL; DOMPERIDONE; DOXORUBICIN; DOXYCYCLINE; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LEVOFLOXACIN; LOPERAMIDE; MITOXANTRONE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; ONDANSETRON; SPARFLOXACIN; TACROLIMUS; TALINOLOL; TERFENADINE; TETRACYCLINE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

BRAIN CAPILLARY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DOG; DRUG ABSORPTION; DRUG DISPOSITION; DRUG SENSITIVITY; DRUG TRANSPORT; ENTERITIS; GENE; GENE DELETION; GENE MUTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTESTINE; KIDNEY TUBULE CELL; MDR 1 GENE; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEIZURE; VETERINARY MEDICINE;

ANIMALS; DRUG INTERACTIONS; GENES, MDR; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; RODENTIA;

EID: 8344244484     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00607.x     Document Type: Review

References (77)

1. Allen, J.D., Van Dort, S.C., Buitelaar, M., van Teilingen, O. & Schinkel, A.H. (2003) Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Research, 63, 1339-1344.
2. Amatori, F.M., Meucci, V., Giusiani, M., Soldani, G., Corazza, M. & Giorgi, M. (2004) Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Veterinary Record, 154, 180-181.
3. Bouer, R., Barthe, L., Philibert, C., Tournaire, C., Woodley, J. & Houin, G. (1999) The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundamental and Clinical Pharmacology, 13, 494-500.
4. Chin, K.V., Ueda, K., Pastan. I. & Gottesman, M.M. (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459-462.
5. Choo, E.F., Leake, B., Wandel. C., Imamura, H., Wood, A.J., Wilkinson, G.R. & Kim, R.B. (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metabolism and Disposition, 28, 655-660.
6. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R. & Bertino, J.R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy of Sciences of the United States of America, 86, 695-698.
7. Cornwell, M.M. (1991) Molecular biology of P-glycoprotein. Cancer Treatment and Research, 57, 37-56.
8. Dahlinger, J., Gregory, C. & Bea, J. (1998) Effect of ketoconazole on cyclosporine dose in healthy dogs, Veterinary Surgery. 27, 64-68.
9. Drozdzik, M., Bialecka, M., Mysliwiec, K., Honczarenko, K., Stankiewicz, J. & Sych, Z. (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics, 13, 259-263.
10. Ericsson, C.D. & Johnson, P.C. (1990) Safety and efficacy of loperamide. American Journal of Medicine, 88, 10S-14S.
11. Fellner, S., Bauer, B., Miller, D.S. et al. (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation, 110, 1309-1318.
12. Ford, J.M. & Hait, W.N. (1993) Pharmacologic circumvention of multidrug resistance. Cytotechnology, 12, 171-212.
13. Fromm, M.F. (2002) Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology, 181-182, 299-303.
14. Hori, R., Okamura, N., Aiba, T. & Tanigawara, Y. (1993) Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. Journal of Pharmacology and Experimental therapeutics, 266, 1620-1625.
15. Hugnet, C., Bentjen, S.A. & Mealey, K.L. (2004) Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. Journal of Veterinary Pharmacology and Therapeutics, 27, 227-229.
16. Hugnet, C., Cadore, J.L., Buronfosse, F., Pineau, X., Mathet, T. & Berny. P.J. (1996) Loperamide poisoning in the dog. Veterinary and Human Toxicology. 38, 31-33.
17. Juliano, R.L. & Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta. 455, 152-162.
18. Juranka, P.P., Zastawny, R.L. & Ling, V. (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB Journal, 3, 2583-2592.
19. Katagiri, A., Tomita, Y., Nishiyama, T., Kimura, M. & Sato, S. (1993) Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer. British Journal of Cancer. 68, 125-129.
20. Kerboeuf, D., Blackball, W., Kaminsky, R. & Samson-Himmelstjerna, G. (2003) P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. International Journal of Antimicrobial Agents, 22, 332-346.
21. Kim, R.B., Fromm, M.F., Wandel, C., Leake, B., Wood, A.J., Roden, D.M. & Wilkinson, G.R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation, 101, 289-294.
22. Kiso, S., Cai, S.H., Kitaichi, K., Furui, N., Takagi, K., Takagi, K., Nabeshima, T. & Hasegawa, T. (2000) Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Research, 20, 2827-2834.
23. Konings, W.N. & Poelarends, G.J. (2002) Bacterial multidrug resistance mediated by a homologue of the human multidrug transporter P-glycoprotein. IUBMB Life, 53, 213-218.
24. Kwei, G.Y., Alvaro, R.F., Chen, Q. et al. (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metabolism and Disposition, 27, 581-587.
25. de Lange, B.C., Marchand, S., van den Berg, D., van der Sandt, I., De Boer, A.C., Delon, A., Bouquet, S. & Couet, W. (2000) In vitro and in vivo investigations on fluoroquinolones: effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. European Journal of Pharmaceutical Science, 12, 85-93.
26. Lankas, G.R., Wise, L.D., Cartwright, M.E., Pippert, T. & Umbenhauer, D.R. (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reproductive Toxicology, 12, 457-463.
27. Li, M., Hurren, R., Zastawny, R.L., Ling. V. & Buick, R.N. (1999) Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium. British Journal of Cancer, 80, 1123-1131.
28. List, A.F., (1997) Non-P-glycoprotein drug export mechanisms of multidrug resistance. Seminars in Hematology, 34, 20-24.
29. Lown, K.S., Mayo, R.R., Leichtman, A.B. et al. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and therapeutics, 62, 248-260.
30. Marzolini, C., Paus, E., Buclin, T. & Kim, R.B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and therapeutics, 75, 13-33.
31. McEntee, M., Silverman, J.A., Rassnick, K., Zgola, M., Chan, A.O., Tau, P.T. & Page, R.L. (2003) Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Veterinary and Comparative Oncology, 2, 105-112.
32. Mealey, K.L., Barhoumi, R., Rogers, K. & Kochevar, D.T. (1998) Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Letters, 126, 187-192.
33. Mealey, K.L., Bentjen, S.A., Gay, J.M. & Cantor, G.H. (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11, 727-733.
34. Mealey, K.L., Bentjen, S.A. & Waiting, D.K. (2002) Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States. American Journal of Veterinary Research, 63, 479-481.
35. Mealey, K.L., Northrup, N.C. & Bentjen, S.A. (2003) Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. Journal of the American Veterinary Medical Association, 223, 1453-1455, 1434.
36. Melaine, N., Lienard, M.O., Dorval, I., Le Goascogne, C., Lejeune, H. & Jegou, B. (2002) Multidrug resistance genes and p-glycoprotein in the testis of the rat, mouse. Guinea pig, and human. Biology of Reproduction, 67, 1699-1707.
37. Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., Scheper, R.J. & Baccarani, M. (1999) P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. British Journal of Haematology, 104, 328-335.
38. Muller, M.B., Keck, M.E., Binder, E.B., Kresse, A.E., Hagemeyer, T.P., Landgraf, R., Holsboer, F. & Uhr, M. (2003) ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology, 28, 1991-1999.
39. Neff, M.W., Robertson, K.R., Wong, A., Safra, N., Broman, K.W., Slatkin, M., Mealey, K.L. & Pedersen, N.C. (2004) Breed distribution and history of canine MDR1-1d, a pharmacogenetic mutation that marks the emergence of breeds of the collie lineage. Proceedings of the National Academy of Sciences, 101, 11725-11730.
40. Page, R.L., Hughes, C.S., Huyan, S., Sagris, J. & Trogdon, M. (2000) Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. Anticancer Research, 20, 3533-3538.
41. Patel, J. & Mitra, A.K. (2001) Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics, 2, 401-415.
42. Patricelli, A.J., Hardie, R.J. & McAnulty, J.E. (2002) Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. Journal of the American Veterinary Medical Association, 220, 1009-1016.
43. Paul, A.J., Tranquilli, W.J., Seward, R.L., Todd, K.S., Jr & DiPietro, J.A. (1987) Clinical observations in collies given ivermectin orally. American Journal of Veterinary Research, 48, 684-685.
44. Raderer, M. & Scheithauer, W. (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer, 72, 3553-3563.
45. Ramage, G., Bachmann, S., Patterson, T.F., Wickes, B.L. & Lopez-Ribot, J.L. (2002) Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biotilms. Journal of Antimicrobial Chemotherapy, 49, 973-980.
46. Rice, A., Michaelis, M.L., Georg, G., Liu, Y., Turunen, B. & Audus, K.L. (2003) Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. Journal of Molecular Neuroscience, 20, 339-343.
47. Roninson, I.B. (1992) The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochemical Pharmacology, 43, 95-102.
48. Sadeque, A.J., Wandel, C., He, H., Shah, S. & Wood, A.J. (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and therapeutics, 68, 231-237.
49. Sakaeda, T., Nakamura, T. & Okumura, K. (2002) MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biological and Pharmaceutical Bulletin, 25, 1391-1400.
50. Sakaeda, T., Nakamura, T. & Okumura, K. (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics, 4, 397-410.
51. Sartor, L.L., Bentjen, S.A., Trepanier, L. & Mealey, K.L. (2004) Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. Journal of Veterinary Internal Medicine, 18, 117-118.
52. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C. & te Riele, H.P. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491-502.
53. Schinkel, A.H., Mol, C.A., Wagenaar, E., van Deemter, L., Smit, J.J. & Borst, P. (1995a) Multidrug resistance and the role of P-glycoprotein knockout mice. European Journal of Cancer, 31A, 1295-1298.
54. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. & Borst, P. (1995b) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Journal of Clinical Investigation, 96, 1698-1705.
55. Schwab, M., Eichelbaum, M. & Fromm, M.F. (2003a) Genetic polymorphisms of the human MDR1 drug transporter. Annual Review of Pharmacology and Toxicology, 43, 285-307.
56. Schwab, M., Schaeffeler, E., Marx, C. et al. (2003b) Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology, 124, 26-33.
57. Schwarz, U.I., Gramatte, T., Krappweis, J., Berndt, A., Oertel, R., von Richter, O. & Kirch, W. (1999) Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clinical Pharmacology and therapeutics, 65, 283-290.
58. Seelig, A. (1998) A general pattern for substrate recognition by P-glycoprotein. European Journal of Biochemistry, 251, 252-261.
59. Siddiqui, A., Kerb, R., Weale, M.E., Brinkmann, U., Smith, A., Goldstein, D.B., Wood, N.W. & Sisodiya, S.M. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New England Journal of Medicine, 348, 1442-1448.
60. Sills, G.J., Kwan, P., Butler, E., de Lange, B.C., van den Berg, D.J. & Brodie, M.J. (2002) P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy and Behavior, 3, 427-432.
61. Song, S., Suzuki, H., Kawai, R. & Sugiyama, Y. (1999) Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metabolism and Disposition, 27, 689-694.
62. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H. & van Teilingen, O. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences of the United States of America, 94, 2031-2035.
63. Sugawara, I. (1990) Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathologica Japonica, 40, 545-553.
64. Sun, J., He, Z.G., Cheng, G., Wang, S.J., Hao, X.H. & Zou, M.J. (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Medical Science Monitor, 10, RA5-RA14.
65. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. & Willingham, M.C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America, 84, 7735-7738.
66. Tranquilli, W.J., Paul, A.J. & Todd, K.S. (1991) Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies. American Journal of Veterinary Research, 52, 1170-1172.
67. Ueda, K., Cardarelli, C., Gottesman, M.M. & Pastan, I. (1987) Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proceedings of the National Academy of Sciences of the United States of America, 84, 3004-3008.
68. Uhr, M., Steckler, T., Yassouridis, A. & Holsboer, F. (2000) Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology, 22, 380-387.
69. Uhr, M., Holsboer, F. & Muller, M.B. (2002) Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. Journal of Neuroendocrinology, 14, 753-759.
70. van Veen, H.W. & Konings, W.N. (1998) The ABC family of multidrug transporters in microorganisms. Biochimica et Biophysica Acta, 1365, 31-36.
71. Volkman, S.K., Cowman, A.F. & Wirth, D.F. (1995) Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 92, 8921-8925.
72. Wandel, C., Kim, R., Wood, M. & Wood, A. (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology, 96, 913-920.
73. West, I.C. (1990) What determines the substrate specificity of the multidrug-resistance pump? Trends in Biochemical Sciences (Cambridge (Eng)), 15, 42-46.
74. Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H.K. & Siegmund, W. (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology and therapeutics, 68, 6-12.
75. Yamaguchi, H., Yano, I., Saito, H. & Inui, K. (2002) Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. Journal of Pharmacology and Experimental therapeutics, 300, 1063-1069.
76. Young, A.M., Alien, C.E. & Audus, K.L. (2003) Efflux transporters of the human placenta. Advanced Drug Delivery Reviews, 55, 125-132.
77. Zhang, Y. & Benet, L.Z. (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics, 40, 159-168.